{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:54:24Z","timestamp":1762642464690,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s13577-021-00495-2","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T18:03:33Z","timestamp":1612202613000},"page":"698-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["mTOR inhibition: a double-edged sword in patients with COVID-19?"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5672-9202","authenticated-orcid":false,"given":"Morteza","family":"Ghasemnejad-Berenji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"issue":"20","key":"495_CR1","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1242\/jcs.051011","volume":"122","author":"M Laplante","year":"2009","unstructured":"Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(20):3589\u201394.","journal-title":"J Cell Sci"},{"key":"495_CR2","doi-asserted-by":"publisher","first-page":"109282","DOI":"10.1016\/j.cbi.2020.109282","volume":"331","author":"A Husain","year":"2020","unstructured":"Husain A, Byrareddy SN. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. Chemico-Biol Interact. 2020;331:109282.","journal-title":"Chemico-Biol Interact"},{"key":"495_CR3","doi-asserted-by":"publisher","first-page":"108464","DOI":"10.1016\/j.clim.2020.108464","volume":"216","author":"L Omarjee","year":"2020","unstructured":"Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Clin Immunol (Orlando, Fla). 2020;216:108464.","journal-title":"Clin Immunol (Orlando, Fla)"},{"issue":"9","key":"495_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/jmv.26009","volume":"92","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID\u201019 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines. J Med Virol 2020;92(9):1495\u20131500.","journal-title":"J Med Virol"},{"issue":"1","key":"495_CR5","first-page":"17","volume":"229","author":"H Yang","year":"2014","unstructured":"Yang H, Wang X, Zhang Y, Liu H, Liao J, Shao K, Chu Y, Liu G. Modulation of TSC\u2013mTOR signaling on immune cells in immunity and autoimmunity. J Cell Physiol. 2014;229(1):17\u201326.","journal-title":"J Cell Physiol"},{"key":"495_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2012.00119","volume":"3","author":"I Halova","year":"2012","unstructured":"Halova I, Draberova L, Draber P. Mast cell chemotaxis\u2013chemoattractants and signaling pathways. Front Immunol. 2012;3:119.","journal-title":"Front Immunol"},{"issue":"10","key":"495_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri3901","volume":"15","author":"T Weichhart","year":"2015","unstructured":"Weichhart T, Hengstschl\u00e4ger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599\u2013614.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"495_CR8","doi-asserted-by":"publisher","first-page":"e01653","DOI":"10.1128\/JVI.01653-16","volume":"91","author":"L YE","year":"2017","unstructured":"Ye L, Lee J, Xu L, Li W, Hale JS, Tan WG, Wu T, Davis CW, Ahmed R, Araki K. mTOR promotes antiviral humoral immunity by differentially regulating CD4 helper T cell and B cell responses. J Virol 2017;91(4):e01653\u201316.","journal-title":"J Virol"},{"key":"495_CR9","doi-asserted-by":"publisher","DOI":"10.1042\/BST20130032","volume-title":"Immune responses of macrophages and dendritic cells regulated by mTOR signalling","author":"K Katholnig","year":"2013","unstructured":"Katholnig K, Linke M, Pham H, Hengstschl\u00e4ger M, Weichhart T. Immune responses of macrophages and dendritic cells regulated by mTOR signalling. London: Portland Press Ltd.; 2013."},{"issue":"3","key":"495_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2174\/1567202617666200425205122","volume":"17","author":"K Maiese","year":"2020","unstructured":"Maiese K. The mechanistic target of rapamycin (mTOR): novel considerations as an antiviral treatment. Curr Neurovasc Res. 2020;17(3):332\u20137.","journal-title":"Curr Neurovasc Res"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-021-00495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13577-021-00495-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-021-00495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T18:08:05Z","timestamp":1614017285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13577-021-00495-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1007\/s13577-021-00495-2","relation":{},"ISSN":["1749-0774"],"issn-type":[{"type":"electronic","value":"1749-0774"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"16 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}